28490813|t|Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma
28490813|a|A hallmark of bone marrow changes with aging is the increase in adipocyte composition, but how this impacts development of multiple myeloma (MM) is unknown. Here, we report the role of the adipokine leptin as master regulator of anti- myeloma tumor immunity by modulating the invariant natural killer T (iNKT) cell function. A marked increase in serum leptin levels and leptin receptor (LR) expression on iNKT cells in MM patients and the 5T33 murine MM model was observed. MM cells and leptin synergistically counteracted anti-tumor functionality of both murine and human iNKT cells. In vivo blockade of LR signalling combined with iNKT stimulation resulted in superior anti-tumor protection. This was linked to persistent IFN-γ secretion upon repeated iNKT cell stimulation and a restoration of the dynamic antigen - induced motility arrest as observed by intravital microscopy, thereby showing alleviation of iNKT cell anergy. Overall our data reveal the LR axis as novel therapeutic target for checkpoint inhibition to treat MM .Leukemia accepted article preview online, 11 May 2017. doi:10.1038/leu.2017.146.
28490813	0	15	Leptin receptor	T103	UMLS:C0385463
28490813	16	26	antagonism	T038	UMLS:C0007613
28490813	30	34	iNKT	T017	UMLS:C2350467
28490813	35	48	cell function	T038	UMLS:C0007613
28490813	77	93	multiple myeloma	T038	UMLS:C0026764
28490813	108	119	bone marrow	T017	UMLS:C0005953
28490813	133	138	aging	T038	UMLS:C0001811
28490813	158	167	adipocyte	T017	UMLS:C0206131
28490813	168	179	composition	T201	UMLS:C0486616
28490813	217	233	multiple myeloma	T038	UMLS:C0026764
28490813	235	237	MM	T038	UMLS:C0026764
28490813	283	292	adipokine	T103	UMLS:C1955907
28490813	293	299	leptin	T103	UMLS:C0299583
28490813	329	351	myeloma tumor immunity	T038	UMLS:C1519680
28490813	370	396	invariant natural killer T	T017	UMLS:C2350467
28490813	398	402	iNKT	T017	UMLS:C2350467
28490813	404	417	cell function	T038	UMLS:C0007613
28490813	428	459	increase in serum leptin levels	T033	UMLS:C2747815
28490813	464	479	leptin receptor	T103	UMLS:C0385463
28490813	481	483	LR	T103	UMLS:C0385463
28490813	499	509	iNKT cells	T017	UMLS:C2350467
28490813	513	515	MM	T038	UMLS:C0026764
28490813	538	544	murine	T103	UMLS:C0591833
28490813	545	547	MM	T038	UMLS:C0026764
28490813	548	553	model	T038	UMLS:C0012644
28490813	568	570	MM	T038	UMLS:C0026764
28490813	571	576	cells	T017	UMLS:C0007634
28490813	581	587	leptin	T103	UMLS:C0299583
28490813	617	641	anti-tumor functionality	T038	UMLS:C1516031
28490813	650	656	murine	T103	UMLS:C0591833
28490813	661	666	human	T204	UMLS:C0086418
28490813	667	677	iNKT cells	T017	UMLS:C2350467
28490813	679	686	In vivo	T082	UMLS:C1515655
28490813	699	701	LR	T103	UMLS:C0385463
28490813	702	712	signalling	T038	UMLS:C1514762
28490813	727	731	iNKT	T017	UMLS:C2350467
28490813	732	743	stimulation	T038	UMLS:C1622572
28490813	765	786	anti-tumor protection	T038	UMLS:C1516031
28490813	818	833	IFN-γ secretion	T038	UMLS:C3156720
28490813	848	852	iNKT	T017	UMLS:C2350467
28490813	853	869	cell stimulation	T038	UMLS:C1622572
28490813	903	910	antigen	T103	UMLS:C0003320
28490813	921	936	motility arrest	T038	UMLS:C2259317
28490813	952	973	intravital microscopy	T058	UMLS:C0596795
28490813	991	1022	alleviation of iNKT cell anergy	T038	UMLS:C2256009
28490813	1052	1054	LR	T103	UMLS:C0385463
28490813	1092	1113	checkpoint inhibition	T038	UMLS:C3544497
28490813	1123	1125	MM	T038	UMLS:C0026764